Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5697221 | Brachytherapy | 2016 | 6 Pages |
Abstract
Approximately one in four men with radiation-managed high-risk PCa do not receive ADT, which may reflect concerns about its toxicity profile despite known improvements in overall survival. Practice patterns suggest that some providers believe dose escalation through brachytherapy boost may obviate the need for ADT in some high-risk patients, but this hypothesis requires further testing.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yu-Wei Chen, Vinayak Muralidhar, Brandon A. Mahal, Michelle D. Nezolosky, Clair J. Beard, Toni K. Choueiri, Karen E. Hoffman, Neil E. Martin, Peter F. Orio, Christopher J. Sweeney, Felix Y. Feng, Quoc-Dien Trinh, Paul L. Nguyen,